KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 80 filers reported holding KEROS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,795 | -88.0% | 12,572 | -84.8% | 0.00% | -100.0% |
| Q2 2023 | $3,330,560 | -10.8% | 82,891 | -5.2% | 0.00% | 0.0% |
| Q1 2023 | $3,731,809 | +578.7% | 87,396 | +663.3% | 0.00% | – |
| Q4 2022 | $549,829 | +81.5% | 11,450 | +42.3% | 0.00% | – |
| Q3 2022 | $303,000 | +6.3% | 8,044 | -21.7% | 0.00% | – |
| Q2 2022 | $285,000 | -48.4% | 10,275 | +1.3% | 0.00% | – |
| Q1 2022 | $552,000 | -15.3% | 10,140 | -9.0% | 0.00% | – |
| Q4 2021 | $652,000 | +52.7% | 11,146 | +3.4% | 0.00% | – |
| Q3 2021 | $427,000 | -9.0% | 10,777 | -2.6% | 0.00% | – |
| Q2 2021 | $469,000 | -20.9% | 11,064 | +14.6% | 0.00% | – |
| Q1 2021 | $593,000 | -19.4% | 9,652 | -7.6% | 0.00% | – |
| Q4 2020 | $736,000 | +394.0% | 10,444 | +171.1% | 0.00% | – |
| Q3 2020 | $149,000 | +12.9% | 3,852 | +9.6% | 0.00% | – |
| Q2 2020 | $132,000 | – | 3,516 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |